---
document_datetime: 2026-02-24 14:03:09
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tivdak-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tivdak-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0061364
conversion_datetime: 2026-02-25 12:00:18.328972
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Tivdak

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C. Safety, efficacy, pharmacovigilance | 23/02/2026                          |                                             | Labelling and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000324286                     | changes - C.z Other variation - Accepted C.z - to update the PI, Labelling and Package Leaflet which do not alter the meaning of the previously approved wording. Editorial, typographical and stylistic changes are also proposed to the national languages to align with the respective sections in the English version.   |            | PL   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type IB / EMA/VR/0000323779 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                      | 20/02/2026 |      |
| Variation type IB / EMA/VR/0000323396 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                      | 18/02/2026 |      |
| Variation type IB / EMA/VR/0000323478 | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                   | 18/02/2026 |      |
| Variation type IB / EMA/VR/0000323050 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                      | 04/02/2026 |      |
| Variation type IB / EMA/VR/0000322257 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where                                                               | 03/02/2026 |      |

<div style=\"page-break-after: always\"></div>

|                                                         | no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                  |            |            |                        |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type IB / EMA/VR/0000322340                   | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted                                                                    | 03/02/2026 |            |                        |
| Variation type IA_IN / EMA/VR/0000267126                | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 14/05/2025 |            |                        |
| Marketing Authorisation Transfer - H / EMA/T/0000267043 | transfer of marketing authorisation from Pfizer Europe MA EEIG to Genmab A/S                                                                                                   | 05/05/2025 | 05/06/2025 | SmPC, Labelling and PL |
| Variation type IA_IN / EMA/VR/0000264661                | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted            | 28/04/2025 | 05/06/2025 | Annex II and PL        |